Compare Amgen, Inc. (AMGN) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Consumer Discretionary Select Sector SPDR Fund trades at $116.88. The key difference: Amgen, Inc. pays a 2.77% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Amgen, Inc. is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| AMGN | XLY | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $124.52 |
52-Week Low | $271.18 | $105.64 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
XLY trades at $117.24, up 0.33% today, with neutral technical signals from oscillators and a bearish moving average trend. Support levels are at $115 and $114, while resistance sits near $118. Analyst consensus is unanimously bullish with a 100% buy rating. Recent news highlights consumer discretionary sector strength amid inflation pressures and holiday spending trends.
The outlook for XLY is positive given strong analyst support, though technical indicators show mixed signals with near-term resistance. Risks include consumer sentiment erosion and inflation impacts on discretionary spending. Upside potential hinges on sustained economic growth and sector outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
